close :

:

Forgotten your password?
 
Professional Information
A-Z Drug Facts > Zanamivir

Zanamivir

Pronouncation: (zan-AM-i-vir)
Class: Antiviral agent

Trade Names:
Relenza
- Powder for oral inhalation 5 mg

Pharmacology

Feedback for Zanamivir

As a treatment for... Avg User Ratings [?]
Influenza Be the first to rate it
Influenza Prophylaxis Be the first to rate it
Compare with other drugs.
Share your Experience Ask a Question

Inhibition of influenza virus neuraminidase, with the possibility of alteration of virus particle aggregation and release.

Pharmacokinetics

Absorption

About 4% to 17% of orally inhaled dose is systemically absorbed. C max is 17 to 142 ng/mL, and T max is 1 to 2 h following a 10 mg dose. The AUC is 111 to 1,364 ng•h/mL.

Distribution

Less than 10% are protein bound.

Metabolism

No metabolites were detected in humans.

Elimination

Renally excreted as unchanged drug in urine. Serum t ½ is 2.5 to 5.1 h. Total Cl is 2.5 to 10.9 L/h. Unabsorbed drug is excreted in feces.

Special Populations

Renal Function Impairment

After IV administration, significant decrease in renal Cl and increase in t ½ (range, 3.1 to 18.5 h). Safety and efficacy have not been documented in severe renal function impairment.

Indications and Usage

Uncomplicated acute illness caused by influenza A and B virus in adults and children at least 7 yr of age who have been symptomatic for no longer than 2 days; prophylaxis of influenza in adults and children 5 yr of age and older.

Contraindications

Standard considerations.

Dosage and Administration

Influenza Treatment
Adults and children at least 7 yr of age

Oral inhalation 2 inhalations (one 5 mg blister per inhalation). Give twice daily (approximately 12 h apart) for 5 days.

Influenza Prophylaxis, Household Setting
Adults and children 5 yr of age and older

Oral inhalation 2 inhalations (one 5 mg blister per inhalation) once daily for 10 days.

Influenza Prophylaxis Community Outbreak
Adults and adolescents

Oral inhalation 2 inhalations (one 5 mg blister per inhalation) once daily for 28 days.

General Advice

  • For oral inhalation only. Not for intranasal inhalation.
  • Initiate therapy within 48 h of onset of influenza symptoms.
  • Administer doses at approximately the same time each day.

Storage/Stability

Store Diskhaler and blister packs at controlled room temperature (59° to 86°F). Do not puncture any blister until just before inhaling a dose.

Drug Interactions

None well documented.

Laboratory Test Interactions

None well documented.

Adverse Reactions

Cardiovascular

Postmarketing

Arrhythmias, syncope.

CNS

Treatment

Dizziness, headache (2%).

Prophylaxis

Headache (13%); fatigue, malaise (5%).

Postmarketing

Seizures.

Dermatologic

Postmarketing

Facial edema, rash, including serious cutaneous reactions.

EENT

Treatment

Ear, nose, throat infections (5%); nasal signs and symptoms (2%).

Prophylaxis

Nasal signs and symptoms (12%); throat and tonsil discomfort and pain (8%); nasal inflammation (1%).

GI

Treatment

Diarrhea, nausea (3%); vomiting (1%).

Prophylaxis

Nausea, vomiting (1%).

Metabolic-Nutritional

Prophylaxis

Feeding problems, including decreased or increased appetite and anorexia (2%).

Musculoskeletal

Prophylaxis

Muscle pain (3%); arthralgia and articular rheumatism (2%).

Respiratory

Treatment

Sinusitis (3%); bronchitis, cough (2%).

Prophylaxis

Viral respiratory infections (13%); cough (7%).

Postmarketing

Bronchospasm, dyspnea.

Miscellaneous

Prophylaxis

Temperature regulation, including fever and chills (5%).

Postmarketing

Allergic or allergic-like reactions, including oropharyngeal edema.

Precautions

Pregnancy

Category C .

Lactation

Undetermined.

Children

Influenza treatment

Safety and efficacy not established in children younger than 7 yr of age.

Influenza prophylaxis

Safety and efficacy not established in children younger than 5 yr of age.

Bacterial infections

Not established for prophylactic use to prevent complications from serious bacterial infections that may begin with influenza-like symptoms.

Bronchospasm

Bronchospasm and decline in lung function have been reported. Discontinue use if this occurs.

High-risk patients

Safety and efficacy not demonstrated in patients with high-risk underlying medical conditions.

Underlying respiratory disease

Safety and efficacy not demonstrated in patients with underlying chronic pulmonary disease (severe COPD or asthma); use is not recommended.

Overdosage

Symptoms

No reports of overdosage. Doses up to 64 mg/day have been given by nebulizer and 1,200 mg/day for 5 days IV.

Patient Information

  • Advise patient to read and carefully follow patient information leaflet before starting therapy.
  • Review and demonstrate proper use of the delivery system.
  • Caution parent or caregiver of child receiving zanamivir that medication should be used only under adult supervision and instruction. Review, and demonstrate if possible, proper use of the delivery system with supervising adult.
  • Review dosing schedule and prescribed length of therapy with patient. Advise patient to inhale contents from 2 blisters twice daily for 5 days. Inform patient that 2 doses should be taken on the first day, provided there is at least 2 h between doses. On subsequent days, doses should be approximately 12 h apart at approximately the same time. Caution patient that medication must be started within 48 h of onset of influenza symptoms in order to be effective.
  • Advise patient using an inhaled bronchodilator at the same time as zanamivir to use the inhaled bronchodilator before inhaling zanamivir.
  • Advise patient that if a dose is missed to take as soon as remembered; however, if it is within 2 h of the time for the next dose, to skip the dose and take the next dose at the regularly scheduled time.
  • Review other modalities for alleviating influenza symptoms (eg, rest, hydration, OTC antipyretics and analgesics).
  • Remind patient to complete entire course of therapy, even if feeling better.
  • Advise patient that medication does not reduce risk of transmission of flu virus to others, and to continue to take appropriate precautions to prevent spreading the infection.
  • Advise patient that zanamivir is not a substitute for flu vaccination and to continue to obtain an annual flu vaccination.
  • Advise patient to inform health care provider if flu symptoms do not appear to be improving or are worsening, or if new symptoms develop during or after treatment.
  • Instruct patient to discontinue therapy and contact health care provider immediately if experiencing increased respiratory symptoms (eg, shortness of breath, worsening wheezing) or signs or symptoms of an allergic reaction (eg, hives, rash, swelling of throat).



More Zanamivir resources:

Drugs.com Relenza

PDR Zanamivir

MedFacts Zanamivir

Micromedex Zanamivir Inhalation?Systemic - Includes detailed dosage instructions.

FDA Relenza

Zanamivir Drug Interactions

Compare Zanamivir with other medications for the treatment of:

Influenza, Influenza Prophylaxis

User Reviews:

0 comment(s) about Zanamivir


Related Drugs
Advertisement
In The Pipeline
Save bookmark to...